Urinary Excretion of the Cancer-Related Glycoprotein EDCI: Effect of Chemotherapy

Publisher Website
Google Scholar
Abstract
The effect of chemotherapy on urinary excretion of a cancer related glycoprotein labeled EDCl, recently isolated from the urine of a patient with acute myelocytic leukemia, was studied by radioimmunoassay in 8 cancer patients who were excreting 200-500 mg/day before treatment. In 5 patients, chemotherapy caused marked clinical improvement, and the glycoprotein disappeared from the urine within 10 days after chemotherapy began. In the 2 patients with solid tumors who responded to chemotherapy, disappearance of glycoprotein EDCl from the urine receded clinical improvement by 1-2 mo. Four of the 5 responsive patients relapsed within 6 mo. In each instance, the glycoprotein reappeared in the urine (> 100 mg/day) 2-5 wk before clinical relapse. Three patients were resistant to chemotherapy, and their urinary glycoprotein did not decline during chemotherapy. Measurement of urinary glycoprotein EDCl will be useful in rapidly ascertaining which drug will be effective in a cancer patient and in predicting relapse.

This publication has 2 references indexed in Scilit: